Comparative Pharmacology
Head-to-head clinical analysis: EPRONTIA versus ZONISADE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPRONTIA versus ZONISADE.
EPRONTIA vs ZONISADE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity in the CNS by inhibiting presynaptic serotonin reuptake.
Zonisamide is a sulfonamide anticonvulsant. Its precise mechanism of action is unknown, but it is believed to inhibit voltage-sensitive sodium channels and reduce T-type calcium currents, thereby stabilizing neuronal membranes and suppressing neuronal hypersynchronization. It may also modulate GABA and glutamate neurotransmission.
Adults: 200-800 mg twice daily orally, starting at 200 mg twice daily, increasing by 200 mg/day weekly to maintenance.
100-200 mg orally every 8 hours; maximum 600 mg/day.
None Documented
None Documented
Terminal elimination half-life is 20–30 hours in adults with normal renal function; prolonged to 40–60 hours in moderate to severe renal impairment (CrCl <50 mL/min), requiring dose adjustment.
Terminal elimination half-life: 63-69 hours in adults; allows once-daily dosing; steady-state achieved in 14-21 days
Renal excretion of unchanged drug accounts for approximately 70% of elimination, with 30% metabolized hepatically; metabolites are also renally excreted. Fecal elimination is minimal (<5%).
Renal: approximately 62% (35% unchanged, 27% as glucuronide conjugate); fecal: 3%; biliary: negligible
Category C
Category C
Anticonvulsant
Anticonvulsant